J9045Carboplatin injection
Published CMS Medicare Part B payment-limit context for J9045, with recent quarterly history and calculated package-level strength context from the CMS crosswalk.
CMS payment limit
$3.153
per 50 MG · Medicare Part B
Up 7.4%from $2.937 in 2026-Q2
- Current quarter
- Billing unit
Payment limit over time
$3.8427$1.8983
2024-Q4: $3.40; 2025-Q1: $3.63; 2025-Q2: $2.93; 2025-Q3: $2.111; 2025-Q4: $2.471; 2026-Q1: $2.929; 2026-Q2: $2.937; 2026-Q3: $3.153
Ingredient appears in FDA shortage dataFDA’s latest completed shortage data includes an affected record matching the Carboplatin ingredient family (FDA data as of August 20, 2026).
Carboplatin
Package figures are calculated from the CMS per-unit payment limit × billable units per package; they are not CMS-published package-level payment limits.
Other Carboplatin presentations
1 other CMS codeSource-linked same ingredient-family context, not recommendations, substitutes, or clinical or billing equivalence.
Swipe to see all columns
| HCPCS | CMS description | Current quarter 2026-Q3 | Prior quarter 2026-Q2 | Change | NDCs | View history |
|---|---|---|---|---|---|---|
| J9278 | Inj, carboplatin (avyxa) | $5.203 per 1 MG | $5.242 per 1 MG | Down 0.7% |
Put another code on your radar.
Browse the CMS directory for published payment-limit context across drugs, NDCs, and source-backed HCPCS Level II drug codes.